BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV) was a top gainer at the close of the week. The stock closed the day with gains of 19.62%. This stock has been gaining since the company made an announcement with regards to its phase 3 trial of its universal influenza vaccine candidate, M-001 on 4th December 2019. At the time, the company announced that, the M-001 trial was fully enrolled.

The participants are made up of 12,463 adults aged 50 years and above, and were assigned to randomly get M-0001 or a placebo. The company also announced that, 4,042 already enrolled in 2018/19 ahead of the 2019/20 influenza season.  From this trial, the company expects a primary outcome of safety, and a decline in illness rates. The trial entails watching the participants for influenza-like symptoms and data will be collected and confirmed in a laboratory. On top of that, immunogenicity makers of M-001 will be analyzed in a sub-group of those taking part in the study.

The company further announced that, analysis of specimens gathered in the study had already been completed in the first 4,094 participants. From these 4,094, 1,135 cases were reported and of those, 137 of them were laboratory-confirmed influenza cases. The company also announced that there had been no safety concerns.

In the announcement, the company stated that results from these trials will be available within 2020 and that in this period, the company will have data on 12,463 people. This will help in determining the effectiveness of M-001 as a treatment for influenza. 

From the charts, the stock has been on the rise, and in Friday’s session, it traded between a low of $6.99 and a high of $8.40 before closing the day at $8.29. Volumes in the day stood at 106.68k.

About BiondVax Pharmaceuticals Ltd

BiondVax Pharmaceuticals Ltd is a biopharma company that develops and sells immunomodulation therapies for infectious diseases. It is headquartered in Jerusalem, Israel.